Ratings Grand Pharmaceutical Group Limited

Equities

512 BMG210A71016

Delayed Hong Kong S.E. Other stock markets 08:10:27 05/06/2024 BST			5-day change	1st Jan Change
5 ^HKD	-3.10%		+2.88%	+22.25%

06-04	Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	CI
04-29	Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Its low valuation, with P/E ratio at 8.19 and 7.17 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company's share price in relation to its net book value makes it look relatively cheap.
This company will be of major interest to investors in search of a high dividend stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GRAND PHARMACEUTICAL GROUP LIMITED	+22.25%	2.31B	-
ELI LILLY AND COMPANY	+42.83%	750B	C+
NOVO NORDISK A/S	+34.11%	606B	B
JOHNSON & JOHNSON	-5.70%	356B	C+
MERCK & CO., INC.	+18.06%	326B	B-
ABBVIE INC.	+4.63%	286B	C+
ASTRAZENECA PLC	+17.64%	246B	B+
NOVARTIS AG	+10.90%	213B	B-
ROCHE HOLDING AG	-3.44%	213B	A+
PFIZER, INC.	+2.43%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes